Skip to main content

Immunity Memory Cells Stay Stable Over Time After Recovery From COVID-19

Written on |

Joint research between TAU and Hasharon Hospital (Rabin Medical Center) proposes the new possibility

Researchers of Tel Aviv University examined blood samples from 60 patients at Hasharon Hospital who had recovered from Corona, and found that memory B cells specific to the virus remain stable over time, but concurrently the antibodies in the blood decrease within just a few months. This finding prompted the researchers to raise the possibility that in the event of re-infection with the virus, symptomatic illness will be insignificant. The research was conducted by Dr. Yariv Wine of Tel Aviv University’s Shmunis School of Biomedicine and Cancer Research, and led by post-doctoral fellow Anna Vaisman-Mentesh, together with Dr. Dror Dicker, Director of the Department of Internal Medicine “D” at Hasharon Hospital, and department’s team.

They don’t forget so quickly

Since the SARS-CoV-2 is a new virus, there is as yet no data on immune memory over time among those recovered from the virus. In the current research, Dr. Wine and team checked the level of antibodies, as well as the B cell count in their group of subjects. As has been shown in other previous studies, the antibodies acting on the viral protein responsible for attaching itself to target cells in the host body, develop very quickly – but decay following recovery. In contrast, B cells, that remember the viral proteins and can efficiently reactivate upon reinfection, do not decline in recovered subjects over a period of six months.

“Corona is a serious illness and includes long-lasting side effects,” Dr. Wine explains. “For that reason, rehabilitation centers have been established for those recovering from Corona, such as the one at Hasharon Hospital, and it also enables us to continue examining blood samples even many months after recovery. From among the group of recovered patients who have volunteered to be part of the research, we collected blood samples at predetermined time intervals – 3 months after onset of disease, and again 3 months later. From the data thus gathered, we can say that over at least a 6 month time period, the subjects maintained a stable level of memory B cells specific to the viral protein. The significance of this is that if these subjects become re-infected, their immune system can quickly respond: B cells will create a secondary reaction which may prevent illness. On the other hand, due to the decay of the antibodies, those who have recovered can still be carriers of the virus, and perhaps also be able to infect others.”

Since the antibodies in the blood of those recovered from Corona decay with time, and in some cases even fall below detection threshold just 3 months after recovery, Dr. Wine and his team fear that serological surveys may be providing an inaccurate picture to decision-makers regarding spread of infection.

Concern over problem in reliability results in serological surveys

“Health organizations and the media talk a lot about serological surveys that check the level of antibodies in the blood, as a way of inferring the spread of disease in the population,” Dr. Wine says. “These surveys are very important, but in the light of the data on the decay of antibodies among recovered subjects, we might get a negative result when testing those who were infected in the past. If the antibodies are not maintained over time, and those who have recovered can still carry the virus and infect others, it is challenging to extrapolate from these surveys the breadth of infection spread in the population.”

Dr. Dicker adds that we are in a process of ongoing learning about Corona virus clinical illness when some recovered subjects still carry the virus. These findings add to our understanding of chronic illness from Corona and may shed light on future capabilities of the immune system of these recovered subjects.

Related posts

Breaking the MedTech Glass Ceiling

27 March 2024

Summer Glow: How Sun Exposure Boosts Fertility in Women Ages 30-40

7 March 2024

Are We Close to Ending Alzheimer’s Memory Loss?

15 February 2024

Destroying Cancer: new drug delivery system containing RNA therapy can target cancer cells in bone marrow

31 July 2023

Stress Makes Vaccines Less Effective

26 July 2023

Researchers Induce Cancer Cell “Suicide”

17 July 2023

Metabolomics – A New Frontier in Preventive Medicine

13 July 2023

Older Bats do Suffer from Age-related Hearing Loss

13 July 2023

Operation Guardian of the Walls: Women, Young People and Residents of the South Paid the Heaviest Price

12 July 2023

Discovery May Lead to Personalized Medicine for Infectious Diseases

12 July 2023

One Third of Normal-Weight Individuals are Obese

12 July 2023

Breakthrough Gene Therapy Offers Hope for Severe Developmental Epilepsy in Children

27 June 2023

Prof. Isaac P. Witz Honored with 2023 Szent-Györgyi Prize for Progress in Cancer Research

26 June 2023

A Step Closer to Beating Melanoma?

18 June 2023

Imagining the Future Patient

13 June 2023

New Treatment Reduces ADHD Symptoms in 1 out of 3 Students

13 June 2023

Victoria

Tok Corporate Centre, Level 1,
459 Toorak Road, Toorak VIC 3142
Phone: +61 3 9296 2065
Email: [email protected]

New South Wales

Level 22, Westfield Tower 2, 101 Grafton Street, Bondi Junction NSW 2022
Phone: +61 418 465 556
Email: [email protected]

Western Australia

P O Box 36, Claremont,
WA  6010
Phone: :+61 411 223 550
Email: [email protected]